Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

Published Date: 13 Sep 2024

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma

2.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

3.

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

4.

Never in a million years did I think I'd have to limit my chemotherapy.

5.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot